Life Expectancy of Patients With CML Approaching That of General Population

Share this content:
A patient undergoes regular chemotherapy.
A patient undergoes regular chemotherapy.

In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with chronic myeloid leukemia (CML) is approaching that of the general population, a study published in the Journal of Clinical Oncology has shown.1

The introduction of imatinib mesylate, the first tyrosine kinase inhibitor approved by the US Food and Drug Administration, led to a substantial improvement in the survival of patients with CML. Therefore, researchers at the Karolinska Institutet in Stockholm, Sweden, sought to evaluate how these changes in the treatment landscape of CML impacted the life expectancy of patients with CML and life-years lost due to CML between 1973 and 2013 in Sweden.

For the study, investigators analyzed data from a total of 2662 patients with CML diagnosed between 1973 and 2013 and included in the Swedish Cancer Registry. Patients were followed until death, censorship, or end of follow-up.

Results showed that life expectancy dramatically improved over the study period, with the largest improvements observed in the youngest patients. Researchers also found that the improvements in life expectancy translated into vast reductions in the loss in expectation of life.

The study further demonstrated that patients whose disease was diagnosed in 2013 will lose an average of fewer than 3 life-years as a result of CML regardless of age.

"This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life," the authors conclude.

The findings also suggest that the increasing prevalence of patients with CML will greatly impact future health care costs as long as continuous treatment with kinase inhibitors in necessary.


1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016 Jun 20. doi: 10.1200/JCO.2015.66.2866.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs